Genesys International closes trading window from Oct 1 for Q2FY27 results
- Trading window closed from October 1, 2026, per SEBI regulations
- Closure applies to Q2FY27 and H1FY27 results declaration
- Window reopens 48 hours after financial results are declared

*this image is generated using AI for illustrative purposes only.
Genesys International Corporation Limited has announced the closure of its trading window effective Thursday, October 1, 2026. This measure is implemented in compliance with the company's Code of Conduct under the SEBI (Prohibition of Insider Trading) Regulations, 2015.
The restriction applies to all designated persons and connected persons dealing in the company's securities. The move ensures that no insider trading occurs during the sensitive period preceding the release of financial performance data.
Reopening timeline and compliance details
The trading window will remain closed until 48 hours after the declaration of the financial results for the quarter and half year ended September 30, 2026. Once this period elapses, trading in the company's securities will be permitted again.
Kushal Jain, Company Secretary and Compliance Officer, confirmed the closure and requested stakeholders to record the same. The company emphasized adherence to regulatory standards to maintain market integrity during the reporting period.
Key dates for investors
| Event | Date | Status |
|---|---|---|
| Trading window closure | October 1, 2026 | Active |
| Financial period end | September 30, 2026 | Completed |
| Window reopening | 48 hours post-declaration | Pending |
Investors should note that any transactions in Genesys International securities during the closed period are prohibited. The company will issue a separate notice regarding the exact date of the board meeting for the approval of these results.
Historical Stock Returns for Genesys International Corp
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.15% | +1.49% | +27.21% | +76.61% | -16.41% | +93.34% |
What specific revenue or margin metrics are analysts expecting for Genesys International's Q2 FY27 results?
How might the upcoming financial results influence institutional investor sentiment given the current valuation multiples?
Are there any pending regulatory approvals or major client contract renewals that could impact the reported performance?


































